Keros Therapeutics Announces $5M Share Repurchase After $20M Takeda Milestone

What Happened

• On September 8, 2026, Keros Therapeutics, Inc. announced that its board approved a new stock repurchase program of up to $5 million of common stock following receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. The company filed the announcement as an 8‑K and attached a press release (Exhibit 99.1).
• As of June 30, 2026, Keros had $257.6 million in cash and cash equivalents. The company says that after giving effect to the $20 million milestone and the $5 million repurchase, its cash position should be sufficient to fund operations and capital expenditures into the second half of 2028.

Key Details

• Share repurchase program authorized: up to $5.0 million.
• Milestone received from Takeda: $20.0 million.
• Cash & cash equivalents (June 30, 2026): $257.6 million.
• Company guidance: cash (after milestone and repurchase) expected to fund operations into H2 2028.
• Filing date: September 8, 2026; press release attached as Exhibit 99.1.

Why It Matters

• The $5M repurchase is a way to return capital to shareholders and may modestly reduce shares outstanding; it is small relative to the company’s cash balance (roughly 1.8–1.9% of June 30 cash depending on treatment of the milestone).
• The $20M milestone from Takeda signals progress under the collaboration/licensing agreement and materially improves near-term liquidity.
• Management’s stated cash runway into the second half of 2028 gives investors a clear timeline for funding operations and development plans without immediate need for additional financing.